EBSEmergent BioSolutions Inc.
$6.81-31% 1Y
$6.81
$4.4552 weeks$13.90
EBS in its own filings
EBS's filing record carries 3 kinds of hard flag, each is shown beside the share of the whole market carrying the same one, because more than half of all companies carry at least one.
466
Events found in the filings · across 1,729 filings · the record starts in 2006
- Hard flags
- 3
Hard flags
- Most recent filing
- Sep 14, 2026
Most recent filing · Form 8-K
- Record starts
- Sep 11, 2006
Record starts · the earliest filing Ryufin holds for this name
Details›
- Next results filingsame week as a year ago
- expected around Oct 28, 2026
- Restatement admitted (non-reliance)past_3y
- 2023-11-16
- Late periodic reportpast_3y
- 2023-11-09
- Delisting notice / listing-rule failurepast_3y
- 2023-11-24
- SEC comment-letter activity27 occurrences
- 2025-08-13
SEC EDGAR submissions index and 8-K item codes; 4.02 and 1.03 items are confirmed against the filing text.
What the company said
The company's own words from its current reports to the SEC, newest first
- Sep 1, 2026On August 18, 2026, Emergent BioSolutions Inc. (“Emergent”) received a contract modification (“Modification No. 21”) of the BARDA AV7909 Contract (as defined below) from the Office of the Assistant Secretary for Preparedness and Response to procure additional doses of CYFENDUS™ (Anthrax Vaccine Adsorbed, Adjuvanted) …Other event · Form 8-K
- Aug 5, 2026On August 5, 2026, the Company announced an organizational restructuring plan (the “Restructuring Plan”) intended to strengthen its long-term financial position in response to changes in its business.Earnings release · Form 8-K
- Jun 29, 2026On June 26, 2026, Emergent BioSolutions Inc. (the “Company,” including its wholly-owned subsidiaries, “Emergent”), through its wholly-owned subsidiary, Emergent Product Development Gaithersburg Inc., received a contract modification from the Office of the Assistant Secretary for Preparedness and Response (“ASPR”), an …Material agreement entered · Form 8-K
- Apr 30, 2026First Quarter 2026 Total Revenues of $156.1 million.Earnings release · press release
- Apr 17, 2026Term Loan Agreement On April 16, 2026, Emergent BioSolutions Inc. (the “Company”) entered into a Credit Agreement (the “Term Loan Agreement”) by and among the Company, the lenders from time to time party thereto, and OrbiMed Royalty & Credit Opportunities V, LP, as administrative agent (the “Term Loan Agent”)Material agreement entered · Form 8-K
- Mar 3, 2026Appointment of John D. Fowler, Jr. as Director On February 25, 2026, the Board of Directors (the “Board”) of Emergent BioSolutions Inc. (the “Company”) appointed John D. Fowler, Jr. as a Class II director effective March 1, 2026, with his initial term expiring at the Company’s 2026 annual meeting of stockholders.Director or officer change · Form 8-K
- Feb 26, 2026Fourth Quarter 2025 Total Revenues of $148.7 million; Full Year 2025 Total Revenues of $742.9 million.Earnings release · press release
- Jan 14, 2026World th 44 Annual J.P. Morgan Healthcare Conference Joe Papa President and Chief Executive Officer January 14, 2026.Regulation FD disclosure · press release
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
opening the record…
Drug Manufacturers, Specialty & Generic
Ranks #31 of 41 by RyuScore